Neurocrine Biosciences (nbix 2.25 05/15/24)
13F holders, Q1 2024 (March 31)6holders
$1.81avg. 13F price*
At the end of Q1 2024, 6 institutions reported holding Neurocrine Biosciences (nbix 2.25 05/15/24) in their 13F filings. The largest holders were Lord, Abbett & Co. LLC ($12.1M), BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.9M) and Jane Street Group, LLC ($352K).
- Company
- Neurocrine Biosciences (nbix 2.25 05/15/24)
- CUSIP
- 64125CAD1
- Latest filing quarter
- Q1 2024
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $48K |
Ownership 6 holders
| Lord, Abbett & Co. LLC | 0.04% | Reduce -45.7% | 6,681,000 | $12.1M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 1,600,000 | $2.9M |
| Jane Street Group, LLC | 0.00% | Reduce -8.4% | 195,000 | $352K |
| Fox Hill Wealth Management | 0.16% | Add +3.9% | 134,000 | $242K |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 10,000 | $18K |
| Capital Analysts, LLC | 0.00% | No change | 2,000 | $4K |
"% of holder's portfolio" is NEUROCRINE BIOSCIENCES (NBIX 2.25 05/15/24)'s weight in each manager's 13F, not the share of Neurocrine Biosciences (nbix 2.25 05/15/24) the manager owns.